What's Happening?
Researchers at Georgetown's Lombardi Comprehensive Cancer Center have identified the RAGE receptor as a key factor in the increased metastasis of breast cancer in older patients. The study, conducted on mouse models and human breast cancer samples, found
that aging enhances inflammatory pathways that activate RAGE, facilitating cancer spread. The findings suggest that inhibiting RAGE could serve as a potential therapeutic strategy to mitigate breast cancer progression in older individuals. The study highlights the role of systemic factors like aging and inflammation in cancer behavior, challenging the focus on genetic mutations alone.
Why It's Important?
This discovery is crucial as it provides a new understanding of how aging influences cancer metastasis, particularly in breast cancer. With older women experiencing higher mortality rates from breast cancer, targeting RAGE could offer a novel treatment approach that is well-tolerated and effective. The research underscores the importance of considering the host environment, including age-related inflammation, in cancer treatment strategies. This could lead to improved outcomes for older patients, who often face limited treatment options due to the toxicity of conventional therapies.
What's Next?
A clinical study is underway at Lombardi to evaluate the safety and efficacy of the RAGE inhibitor TTP488 in breast cancer patients undergoing chemotherapy. This drug has shown promise in preclinical models and has a favorable safety profile, making it a viable candidate for repurposing in cancer therapy. The study aims to assess the drug's impact on cognitive outcomes and its potential to reduce metastasis, offering hope for better management of breast cancer in the elderly.
